劉 俊煌

Medicine & Life Sciences

1. Acute Myeloid Leukemia 28%
2. Acute Promyelocytic Leukemia 16%
3. B-Cell Lymphoma 22%
4. Bone Marrow 25%
5. Bone Marrow Transplantation 33%
6. Carcinoembryonic Antigen 19%
7. Carcinoma 16%
8. Cohort Studies 16%
9. Colorectal Neoplasms 73%
10. Cytarabine 19%
11. Drug Therapy 49%
12. Fever of Unknown Origin 14%
13. Fluorouracil 48%
14. Gene Rearrangement 37%
15. General Hospitals 15%
16. Graft vs Host Disease 31%
17. Hematopoietic Stem Cell Transplantation 78%
18. Hepatitis B 18%
19. Hepatitis B virus 23%
20. Homologous Transplantation 18%
21. Imatinib Mesylate 16%
22. Immunoglobulin Genes 16%
23. Infections 18%
24. Irinotecan 17%
25. Leucovorin 54%
26. Leukemia 24%
27. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 28%
28. Lymphocyte Count 20%
29. Lymphoma 40%
30. Lymphoma, Large B-Cell, Diffuse 46%
31. Mortality 19%
32. Multiple Myeloma 48%
33. Neoplasms 27%
34. Non-Hodgkin's Lymphoma 71%
35. Oxaliplatin 28%
36. Rituximab 42%
37. Salvage Therapy 31%
38. Stem Cell Transplantation 20%
39. Survival 63%
40. T-Cell Lymphoma 19%
41. T-Cell Receptor Genes 15%
42. Taiwan 100%
43. Tegafur 16%
44. Therapeutics 26%
45. Transplants 23%
46. Uracil 14%
47. Veterans Hospitals 21%